Ventilators are the most important tool to save the lives of those suffering with COVID-19. The novel coronavirus attacks the lungs, and those worst hit need ventilators to breathe. With demand for the critical piece of medical technology far outstripping the number in production, companies are racing against the clock to design, manufacture, and deliver the life-saving devices.
Based on overseas experience,
20 per cent
of COVID-19 sufferers require hospitalisation, while
five per cent
require intensive care, often involving ventilation.
These ventilation machines support patients who can no longer control their own breathing by getting oxygen to the lungs and removing carbon dioxide through a tube inserted into the mouth or nose.
Australia currently has
2,300 intensive care units
with ventilators, however with the increase in COVID-19 sufferers the government is looking to introduce another
5,000
ventilators.
The government has ordered
1,000
invasive ventilators from MedTech company ResMed, who will also be producing non-invasive ventilators, along with companies General Electric (GE) Healthcare, Philips and Medtronic.
“We are working with governments, health authorities, hospitals, physicians and patients worldwide to assess their needs and to deliver the ventilation therapy that is essential to treat the respiratory complications of COVID-19,” ResMed’s CEO, Mark Farrell, said.
The company is focusing on better understanding where the immediate need is so their devices can be shipped and instantly used on a patient, according to a ResMed spokesperson.
Farrell explains ResMed’s ventilators are cloud-connected, allowing healthcare workers to monitor their patients remotely. He adds this remote monitoring is needed in the current crisis with a virus so contagious that stems from direct human contact.
ResMed is focusing on maximising the availability of their ventilators, masks and other respiratory devices.
Farrell said, “the company is looking to double or triple the output of ventilators and scale up on ventilation mask production more than tenfold.”
ResMed told Innovation Intelligence
that greater access to ventilators will be achieved with the effort to slow down the spread of the virus by staying home, social distancing and following health guidelines.
“The sooner we slow down the spread of this virus, the faster we lower the demand for ventilators and other devices needed to treat its deadly symptoms,” a spokesperson said.
The Australian government is also seeking help from carmaker Ford, who has teamed up with 3M and General Electric Healthcare to produce medical equipment and protective gear for healthcare workers.
Ford is working with 3M to produce a new powered air-purifying respirator for healthcare workers, while also increasing the production of 3M’s and GE Healthcare’s current respirator devices.
Engineering company Dyson, known for its vacuum cleaners and dryers, also responded to this demand with their new ventilation prototype, CoVent, which was designed and built 10 days after the United Kingdom (UK) government asked for the company’s help, according to its founder, James Dyson.
The prototype is yet to pass through mandatory medical testing, however the government has ordered 10,000 ventilators if it is successful.
“This new device can be manufactured quickly, efficiently and at volume, with a design to address the specific needs of the patients,” Dyson explained.
He said, “the race is now on to get it into production,” with a company spokesperson adding the ventilators could be ready by early April.
Dyson will be donating
five thousand
ventilators to aid global efforts to fight COVD-19, with one thousand of them reserved for the UK.
Other companies such as GTech, Tesla and General Motors have also responded to the governments demands with their own plans to build and distribute ventilators quickly.
A ResMed spokesperson told Innovation Intelligence
that, while the assistance automakers are providing is welcome, due to the difficulty in obtaining enough parts for ventilators, they would discourage them pulling from the already scarce supply of parts to build their own clinically untested products.